Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
In this nationwide cohort study of patients with SLE, a protective association was found between the current use of hydroxychloroquine and the occurrence of CV events, but not between remote use of hydroxychloroquine and CV outcomes, highlighting the value of continuous hydroxychloroquine treatment in patients with SLE.
Authors
- Yann Hamon
- Lucien Abenhaim
- Albert Buchard
- Lamiae Grimaldi‐Bensouda (ORCID: https://orcid.org/0000-0003-1952-5467)
- Jacques Bénichou (ORCID: https://orcid.org/0000-0003-3160-9110)
- N. Costedoat‐Chalumeau (ORCID: https://orcid.org/0000-0002-1555-9021)
- Yola Moride
- Tom Duchemin
Institutions
- Rutgers, The State University of New Jersey (US)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris Cité (FR)
- London School of Hygiene & Tropical Medicine (GB)
- Sorbonne Paris Cité (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- French Norwegian Foundation (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.32190
- Citations
- 13
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 6.11
Funders
- Union Chimique Belge
- Foundation for Research in Rheumatology